Plasmid DNA Manufacturing Market - Industry Analysis, Covid-19 Impact of Market

Plasmid DNA Manufacturing Market Overview

Driven by the expanding landscape of cell and gene therapy, plasmid manufacturer are capturing substantial interest from drug developers. Plasmids are circular, double-stranded DNA molecules that exist autonomously within the bacterial cells, independent of the chromosomal DNA.

The global plasmid DNA manufacturing market size is estimated to grow from USD 102 million in 2023 to USD 539 million by 2035, representing a CAGR of 14.85% during the forecast period 2023-2035.

These genetic components have the ability to replicate independently. Additionally, plasmids often carry non-essential genetic information that confers supplementary traits to host organisms. This genetic autonomy, combined with its compact circular structure, lends plasmid DNA unparalleled versatility and utility. Furthermore, its role in the development of recombinant proteins and therapeutic agents has significantly influenced the landscape of modern medicine.

In 2035, more than 35% of the demand for plasmid DNA is likely to be generated by gene therapy-based products, across clinical and commercial scales. Over the years, the approval of more than 50 cell and gene therapy products, including KYMRIAH[1], YESCARTA[2], LUXTURNA[3], ZOLGENSMA[4] across various geographies has significantly contributed to the surge in demand for plasmid DNA. These therapies have demonstrated promising results in treating a wide range of diseases, leading to a greater need for plasmid DNA as a crucial component for their production. Additionally, the extensive evaluation of over 1,300 clinical trials focusing on advanced therapy medicinal products (ATMPs) has further intensified the demand for plasmid production.

The demand for commercial scale plasmid manufacturing is driven by a larger target patient population as compared to clinical drugs. Further, the maximum commercial demand for plasmid DNA is likely to be driven by North America, followed by Europe. The estimated plasmid DNA manufacturing market opportunity is expected to be well distributed across different scales of operation, therapeutic areas, application areas and geographies.

Plasmid DNA Manufacturing Market Competitive Landscape

Key players in Plasmid DNA Manufacturing Market are AGC Biologics, Aldevron, Biomay, Catalent Pharma Solutions, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, Thermo Fisher Scientific, and VGXI. As per the base case forecast scenario, the market for plasmid DNA manufacturing services is estimated to grow at a CAGR of ~15%, during the forecast period. We anticipate integration of novel technologies and increasing trend of outsourcing plasmid manufacturing operations will propel the market growth, during the forecast period.

The opportunity is likely to be well distributed different scales of operation, therapeutic areas, application areas and geographies, during the forecast period. Further, in terms of scale of operation, commercial products presently capture the largest global market share, followed by clinical products and preclinical products. In addition, viral vector manufacturing is expected to capture highest market share based on type of application area, till 2035.

Browse Complete Report at: https://www.rootsanalysis.com/reports/plasmid-dna-manufacturing-market.html

Browse More Related Promotions:-

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.

All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.

Contact Details

Roots Analysis

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com

Website: https://www.rootsanalysis.com/